Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with ...

According to US secondary stroke prevention guidelines, patients with ESUS should not be treated with anticoagulants or ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Today, the Lonza Board of Directors announced the nomination of Juan Andres and Eric Drapé as Independent Members of the Board. The Board will propose to shareholders the election of both nominees at ...